[Version 9,03/2022]

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

In Belgium, Bulgaria, Czech Republic, France, Germany, Greece, Hungary, Italy, Poland, Portugal, Romania, Slovakia, Spain and The Netherlands;

LUTEOSYL 0.075 mg/ml solution for injection for cattle and pigs.

In United Kingdom: Prellim 0.075 mg/ml solution for injection for cattle and pigs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substance:

d-Cloprostenol (as d-Cloprostenol sodium).....0.075 mg

Excipients:

Qualitative composition of excipients and other constituents	**Quantitative composition if that information is essential for proper administration of the veterinary medicinal product**
Chlorocresol	1 mg
Ethanol (96%)	
Citric acid monohydrate	
Sodium hydroxide	
Water for injections	

Clear, colourless solution for injection, free from particles in suspension.

3. CLINICAL INFORMATION

3.1. Target species

Cattle (cows) and pigs (sows).

3.2 Indications for use for each target species

Cattle (cows)
Indications for reproduction: synchronization or induction of oestrus. Induction of parturition.
Therapeutic indication: ovarian dysfunction (persistent corpus luteum, luteal cyst), interruption of pregnancy including foetal mummification, endometritis/pyometra, delayed uterine involution.

Pigs (sows)
Indications for reproduction: Induction of parturition.

3.3 Contraindications

See section 3.7
Do not use in cases of hypersensitivity to the active substance, or to any of the excipients.
Do not use in animals with spastic respiratory or gastro-intestinal diseases.

3.4 Special warnings

None.

3.5 Special precautions for use

Special precautions for safe use in the target species

As with parenteral administration of any substance, basic antiseptic rules should be observed. The injection site must be thoroughly cleaned and disinfected in order to reduce the risk of infection with anaerobic bacteria.
Pigs: use only when precise date of insemination is known. Administer on day 113 of gestation, at the earliest. The veterinary medicinal product administered earlier, may impair the viability and weight of piglets.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

d-Cloprostenol, like all $F_{2\alpha}$ prostaglandins, can be absorbed through the skin and can produce bronchospasm and abortion.
Direct contact with skin or mucous membranes of the user should be avoided. Pregnant women, women of child-bearing age, asthmatics and persons with bronchial problems or any other type of respiratory problem must avoid any contact or use disposable plastic gloves when administering the veterinary medicinal product.
The veterinary medicinal product must be handled carefully to avoid ACCIDENTAL SELF-INJECTION OR SKIN CONTACT.
In case of accidental self injection seek medical advice immediately and show the package leaflet or the label to the physician.
Seek medical advice immediately in case of any respiratory difficulty caused by accidental inhalation or inoculation.
In case of accidental skin contact, wash with soap and water immediately.
Do not eat, drink or smoke while handling the veterinary medicinal product.

Special precautions for the protection of the environment:
Not applicable

3.6 Adverse events

Cattle and pigs

Very rare (< 1 animal / 10,000 animals treated, including isolated reports):	Application site reaction[1] Injection site swelling[1] Injection site gaseous gangrene[1]

[1] Typical local reactions due to anaerobic infection applies in particular to cows.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also section 16 of the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy:
Do not use (during the whole or part of the pregnancy) unless it is desirable to induce parturition or therapeutic interruption of pregnancy.

3.8 Interaction with other medicinal products and other forms of interaction

Do not use in animals being treated with non-steroidal anti-inflammatories, as the synthesis of endogenous prostaglandins is inhibited.
The activity of other oxytocic agents can be increased after the administration of Cloprostenol.

3.9 Administration routes and dosage

For intramuscular use only:

Cattle(cows): The recommended dose is 0.150 mg d-cloprostenol/animal, equivalent to 2 ml/animal.
- **Oestrus induction** (also in cows with weak or silent heat): After determining the presence of corpus luteum (day 6-18 of the cycle), administer the veterinary medicinal product. Heat is generally observed in 48-60 hours. Inseminate 72-96 hours after this treatment. If heat is not observed, repeat after 11 days.
- **Parturition induction**: Administer the veterinary medicinal product after gestation day 270. Parturition should occur 30-60 hours post-treatment.
- **Oestrus synchronisation**: Administer the veterinary medicinal product twice (11 days apart). Inseminate artificially 72 and 96 hours after the second injection.
  Based on the results of clinical trials and the scientific literature, d-cloprostenol can be used in combination with GnRH, with or without progesterone, in ovulation synchronization protocols (Ovsynch protocols). The decision on which protocol to use should be made by the responsible veterinarian, based on the objectives of the treatment and depending on the herd and animals to be treated. The following protocols have been evaluated and can be used:
  In cycling cows:
    - Day 0: inject GnRH (or analog).
    - Day 7: inject d-cloprostenol (2 ml of the veterinary medicinal product).
    - Day 9: inject GnRH (or analog).
    - Artificial insemination 16-24 hours later.

  Alternatively in cycling and non-cycling cows and heifers:
    - Day 0: insert the intravaginal progesterone releasing device and inject GnRH (or analog).
    - Day 7: remove the intravaginal device and inject d-cloprostenol (2 ml of the veterinary medicinal product).
    - Day 9: inject GnRH (or analog).
    - Artificial insemination 16-24 hours later.
- **Ovarian dysfunction**: Once the presence of corpus luteum is determined, administer the veterinary medicinal product and inseminate in the first heat after the treatment. If no heat is observed, carry out a gynaecological examination again and repeat the injection 11 days after the first treatment. Insemination is 72-96 hours post-treatment.
- **Endometritis or pyometra**: Administer 1 dose of the veterinary medicinal product. Repeat the treatment 10-11 days later if necessary.
- **Gestation interruption**: Administer the veterinary medicinal product during the first half of gestation.
- **Foetal mummification**: Administer 1 dose of veterinary medicinal product. The foetus will be expelled after 3 or 4 days.
- **Retarded uterine involution**: Administer 1 dose of the veterinary medicinal product and, if indicated, repeat the treatment once or twice at 24 hours interval.

Pigs(sows): The recommended dose is 0.075 mg d-cloprostenol/animal, equivalent to 1 ml/animal.
- **Parturition induction**: Administer the veterinary medicinal product after day 112 of gestation. Repeat after 6 hours. Alternatively, 20 hours after the initial dose of d-cloprostenol, a myometrial stimulant (oxytocin or carazolol) may be administered. Following the protocol of double administration, in about 70% of cases, parturition occurs 20-30 hours after the first treatment.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

In safety studies, at 10 times the therapeutic dose, no adverse reactions are reported.
As no specific antidote has been identified, in the case of overdose, symptomatic therapy is advisable.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

<To be completed in accordance with national requirements after conclusion of the MRP.>

3.12 Withdrawal periods

Cows: Meat and offal: 1 day.
Milk: Zero hours.
Sows: Meat and offal: 1 day.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QG02AD90.

4.2 Pharmacodynamics

The veterinary medicinal product is based on dextrorotatory cloprostenol (d-Cloprostenol), a synthetic analogue of prostaglandin $F_{2\alpha}$.
d-Cloprostenol is the biologically active luteolytic component of cloprostenol and results in an approximately 3.5-fold increase in activity.
During the luteinizing stage of the oestrus cycle d-cloprostenol induces a rapid regression of the corpus luteum and a decrease in progesterone levels. The increased release of follicle stimulating hormone (FSH) allows a new follicle to mature, followed by oestrus and ovulation.

4.3 Pharmacokinetics

Pharmacokinetic studies demonstrate a rapid absorption of d-cloprostenol. The peak blood level is reached a few minutes following intramuscular administration, as well as a rapid diffusion to the ovaries and uterus, the organs in which the maximum concentration is reached 10-20 minutes after administration.
Following intramuscular administration of 150 micrograms of d-cloprostenol in the cow, the peak plasma level (C_{max}) of 1.4 micrograms/l is reached after approximately 90 minutes, while the elimination half life ($t_{½}$) is in the order of 1 hour 37 minutes.
In sows, a C_{max} of approximately 2 micrograms/l is observed between 30 and 80 minutes following administration of 75 micrograms d-cloprostenol, with an elimination half life in the order of 3 hours 10 minutes.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening the immediate packaging: 28 days.

5.3 Special precautions for storage

Keep the vial in the outer carton in order to protect from light.

5.4 Nature and composition of immediate packaging

Colourless type II glass vial with type I bromobutyl rubber stopper and aluminium cap.

Package size:

1 glass vial of 20 ml in a cardboard box.
5 glass vials of 20 ml in a cardboard box

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater <or household waste>.
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Laboratorios Syva S.A.

7. MARKETING AUTHORISATION NUMBER(S)

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: DD/MM/YYYY

9. DATE OF THE LAST REVISION OF THE SUMMARY OF PRODUCT CHARACTERISTICS

Month/YYYY

10. CLASIFICATION OF THE VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.
Detailed information on this veterinary medicinal product is available in the Union Product Database

ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Box with 1 vial of 20 ml
Box with 5 vials of 20 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

In Belgium, Bulgaria, Czech Republic, France, Germany, Greece, Hungary, Italy, Poland, Portugal, Romania, Slovakia, Spain and The Netherlands;

LUTEOSYL 0.075 mg/ml solution for injection.
In United Kingdom: Prellim 0.075 mg/ml solution for injection.

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains:

d-Cloprostenol (as d-Cloprostenol sodium) 0.075 mg

3. PACKAGE SIZE

20 ml
5 x 20 ml

4. TARGET SPECIES

Cattle (cows) and pigs (sows).

5. INDICATION(S)

6. ROUTE(S) OF ADMINISTRATION

Intramuscular use.

7. WITHDRAWAL PERIOD

Withdrawal period:
Cows: Meat and offal: 1 day.
Milk: Zero hours.
Sows: Meat and offal: 1 day.

8. EXPIRY DATE

Exp. {mm/yyyy}
Once opened, used within 28 days.
Once opened used by …

9. SPECIAL STORAGE PRECAUTIONS

Keep the vial in the outer carton in order to protect from light

10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"

Read the package leaflet before use

11. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only

12. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Laboratorios Syva S.A.

14. MARKETING AUTHORISATION NUMBER(S)

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL INMEDIATE PACKAGE UNITS
VIAL OF 20 ML

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

In Belgium, Bulgaria, Czech Republic, France, Germany, Greece, Hungary, Italy, Poland, Portugal, Romania, Slovakia, Spain and The Netherlands;

LUTEOSYL 0.075 mg/ml solution for injection.
In United Kingdom: Prellim 0.075 mg/ml solution for injection

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCE

Each ml contains:
d-Cloprostenol (as d-Cloprostenol sodium).....0.075 mg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}
Once opened, used within 28 days.
Once opened used by…

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

In Belgium, Bulgaria, Czech Republic, France, Germany, Greece, Hungary, Italy, Poland, Portugal, Romania, Slovakia, Spain and The Netherlands:

LUTEOSYL 0.075 mg/ml solution for injection for cattle and pigs.
In United Kingdom: Prellim 0.075 mg/ml solution for injection for cattle and pigs

2. Composition

Each ml contains:

Active substance:
d-Cloprostenol (as d-Cloprostenol sodium).....0.075 mg

Excipients:
Chlorocresol.....1 mg

Clear, colourless solution for injection, free from particles in suspension.

3. Target species

Cattle (cows) and Pigs (sows).

4. Indications for use

Cattle (cows)
Indications for reproduction: synchronization or induction of oestrus. Induction of parturition.
Therapeutic indication: ovarian dysfunction (persistent corpus luteum, luteal cyst), interruption of gestation including foetal mummification, endometritis/pyometra, delayed uterine involution.
Pigs (sows)
Indications for reproduction: Induction of parturition.

5. Contraindications

Do not use (during the whole or part of the pregnancy) unless it is desirable to induce parturition or therapeutic interruption of pregnancy. Do not use in case of hypersensitivity to the active substance, or to any of the excipients. Do not use in animal with spastic respiratory or gastro-intestinal diseases.

6. Special warnings

Special warnings:
None.

Special precautions for safe use in the target species :

As with parenteral administration of any substance, basic antiseptic rules should be observed. The injection site must be thoroughly cleaned and disinfected in order to reduce the risk of infection with anaerobic bacteria.

Pigs: use only when precise date of insemination is known. Administer on day 113 of gestation, at the earliest. The veterinary medicinal product administered earlier, may impair the viability and weight of piglets.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

d-Cloprostenol, like all $F_{2\alpha}$ prostaglandins, can be absorbed through the skin and can produce bronchospasm and abortion.
Direct contact with skin or mucous membranes of the user should be avoided. Pregnant women, women of child-bearing age, asthmatics and persons with bronchial problems or any other type of respiratory problem must avoid any contact or use disposable plastic gloves when administering the veterinary medicinal product.
The veterinary medicinal product must be handled carefully to avoid ACCIDENTAL SELF-INJECTION OR SKIN CONTACT.
In case of accidental self injection seek medical advice immediately and show the package leaflet or the label to the physician.
Seek medical advice immediately in case of any respiratory difficulty caused by accidental inhalation or inoculation.
In case of accidental skin contact, wash with soap and water immediately.
Do not eat, drink or smoke while handling the veterinary medicinal product.

Pregnancy.
Do not use (during the whole or part of the pregnancy) unless it is desirable to induce parturition or therapeutic interruption of pregnancy.

Interaction with other medicinal products and other forms of interaction:
Do not use in animals being treated with non-steroidal anti-inflammatories, as the synthesis of endogenous prostaglandins is inhibited.
The activity of other oxytocic agents can be increased after the administration of Cloprostenol.

Overdose:
In safety studies, at 10 times the therapeutic dose, no adverse reactions are reported.
As no specific antidote has been identified, in the case of overdose, symptomatic therapy is advisable.

Special restrictions for use and special conditions for use:
<To be completed in accordance with national requirements after conclusion of the MRP.>

Major incompatibilities
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

7. Adverse events

Cattle and pigs

Very rare (< 1 animal/ 10,000 animals treated, including isolated reports):
Application site reaction[1] Injection site swelling[1] Injection site gaseous gangrene[1]

[1] Typical local reactions due to anaerobic infection applies in particular to cows.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has

not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder, the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: <{national system details}[listed in Appendix I*]>.

8. Dosage for each species, routes and method of administration

This veterinary medicinal product is only for intramuscular use:
Cattle (cows): The recommended dose is 0.150 mg d-cloprostenol/animal, equivalent to 2 ml/animal.
- Oestrus induction (also in cows with weak or silent heat): Administer the veterinary medicinal product after the presence of corpus luteum has been determined (6^{th}-18^{th} day of the cycle). Heat is normally observed after 48-60 hours. Inseminate 72-96 hours after the previous treatment.
If heat is not observed, repeat after 11 days.
- Parturition induction: Administer the veterinary medicinal product after the 270^{th} day of gestation. Parturition should occur 30-60 hours after treatment.
- Oestrus synchronization: Administer the veterinary medicinal product twice (11 days apart). Inseminate artificially 72 and 96 hours after the second injection.
Based on the results of clinical trials and the scientific literature, d-cloprostenol can be used in combination with GnRH, with or without progesterone, in ovulation synchronization protocols (Ovsynch protocols). The decision on which protocol to use should be made by the responsible veterinarian, based on the objectives of the treatment and depending on the herd and animals to be treated. The following protocols have been evaluated and can be used:
In cycling cows:

- Day 0: inject GnRH (or analog).
- Day 7: inject d-cloprostenol (2 ml of the veterinary medicinal product).
- Day 9: inject GnRH (or analog).
- Artificial insemination 16-24 hours later.

Alternatively in cycling and non-cycling cows and heifers:

- Day 0: insert the intravaginal progesterone releasing device and inject GnRH (or analog).
- Day 7: remove the intravaginal device and inject d-cloprostenol (2 ml of the veterinary medicinal product).
- Day 9: inject GnRH (or analog).
- Artificial insemination 16-24 hours later.

- Ovarian dysfunction: After the presence of corpus luteum has been determined, administer the veterinary medicinal product and inseminate during the first heat after treatment. If no heat is observed, carry out another gynaecological examination and repeat the injection 11 days after the first treatment. Inseminate 72-96 hours after treatment.
- Endometritis or pyometra: Administer 1 dose of veterinary medicinal product. Repeat treatment 10-11 days later if necessary.
- Gestation interruption: Administer the veterinary medicinal product during the first half of gestation.
- Foetal mummification: Administer 1 dose of veterinary medicinal product. The foetus is expelled 3 or 4 days later.
- Retarded uterine involution: Administer 1 dose of veterinary medicinal product and, if indicated, repeat treatment once or twice at 24 hours interval.

Pigs (sows): The recommended dose is 0.075 mg d-cloprostenol/animal, equivalent to 1 ml/animal.
- Parturition induction: Administer the veterinary medicinal product after day 112 of gestation. Repeat after 6 hours. Alternatively, 20 hours after the initial dose of d-cloprostenol, a myometrial stimulant (oxytocin or carazolol) may be administered. Following the protocol of double administration, in about 70% of cases, parturition occurs 20-30 hours after the first treatment.

9. Advice on correct administration

As with parenteral administration of any substance, basic antiseptic rules should be observed. The injection site must be thoroughly cleaned and disinfected in order to reduce the risk of infection with anaerobic bacteria.

10. Withdrawal periods

Cows:
Meat and offal: 1 day.
Milk: Zero hours.
Sows:
Meat and offal: 1 day.

11. Special storage precautions

Keep out of the sight and reach of children.
Keep the vial in the outer carton in order to protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp.. The expiry date refers to the last day of that month.

Shelf life after first opening the container: 28 days.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater <or household waste>.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your <veterinary surgeon> <or> <pharmacist> how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorization numbers and pack sizes

Package size:

1 glass vial of 20 ml in a cardboard box.
5 glass vials of 20 ml in a cardboard box

Not all pack sizes may be marketed.

15. Date on which the package leaflet was revised

{Month YYYY}
Detailed information on this veterinary medicinal product is available in the Union Product Database.

16. Contact details

Marketing authorisation holder:
Laboratorios Syva S.A.
Calle Marqués de la Ensenada, 16
28004 MADRID
ESPAÑA

Manufacturer responsible for batch release:
Laboratorios Syva S.A.
Avenida del Párroco Pablo Díez, 49-57
San Andrés del Rabanedo
24010 LEÓN
ESPAÑA

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

Local representatives and contact details to report suspected adverse reactions:

België/Belgique/Belgien
Local representative:
Fendigo sa/nv
Avenue Herrmann Debrouxlaan 17
B-1160 Bruxelles/Brussel/Brüssel
Tél/Tel: + 32 2 734 48 21
Contact details to report suspected adverse reactions:
Fendigo sa/nv
Tél/Tel: + 32 474 97 09 88
E-mail: PHV@fendigo.com

Република България
Local representative:
Фарма Сис ООД
гр. Пловдив, ул. Подофицер Георги Котов 1
България, 4000 Пловдив
Тел: + 359 58/604-266
E-mail: farmasys@abv.bg
Contact details to report suspected adverse reactions:
Фарма Сис ООД
Тел: + 359 58 604266
E-mail: farmasys@abv.bg

Česká republika
Contact details to report suspected adverse reactions:
Vele spol. s.r.o.
Tel: +420 567 275 046
E-mail: odbyt@velelecivа.cz

Magyarország
Local representative:
Alpha-Vet Állatgyógyászati Kft.
8000 Székesfehérvár, Homoksor 7.
Tel.: + 36-22-534500
Contact details to report suspected adverse reactions:
Alpha-Vet Állatgyógyászati Kft.
Tel.: +36 30 5011484
E-mail: kun.csaba@alpha-vet.hu

Deutschland
Local representative:
BELA-PHARM GMBH & CO. KG
Lohner Str. 19
D-49377 Vechta
Tel: + 04441 873 0
Contact details to report suspected adverse reactions:
BELA-PHARM GMBH & CO. KG
Tel: + 49 4441 873 555
E-mail: pharmacovigilance@bela-pharm.com

Ελλάδα
Local representative:
Premier Shukuroglou Hellas S.A.
Τηλ: + 30 210 6538061
Email: psh@premier.com.gr
Contact details to report suspected adverse reactions:
Premier Shukuroglou Hellas S.A.
Τηλ: + 30 6947619393
E-mail: pvreport@premier.com.gr

France
Local representative and contact details to report suspected adverse reactions:
Laboratoires Biové
3, rue de Lorraine
62510 Arques, France
Tél: + 33 6 46 52 48 06
E-mail : pv@inovet.eu

România
Contact details to report suspected adverse reactions:
DEAVET Srl
Tel: +40722347218
E-mail: toni@deavet.ro

Nederland
Local representative:
Fendigo sa/nv
Avenue Herrmann Debrouxlaan 17
B-1160 Brussel
Tel: + 32 2 734 48 21
Contact details to report suspected adverse reactions:
Fendigo sa/nv
Tel: + 32 474 97 09 88
E-mail: PHV@fendigo.com

España
Contact details to report suspected adverse reactions:
Laboratorios Syva S.A.
Parque Tecnológico de León
Calle Nicostrato Vela M15-M16
24009 LEÓN
ESPAÑA
Tel: + 34 987 800 800
E-mail: farmacovigilancia@syva.es

Polska
Local representative:
Grabikowski-Grabikowska PPHU „INEX" Sp.j.
ul. Białostocka 12, 11-500 Giżycko, Polska
Tel.: +48 87 429 17 19
Contact details to report suspected adverse reactions:
Grabkowski-Grabikowska PPHU „INEX" Sp.j.
Tel.: + 48 795 128 650
E-mail : bezpieczenstwo@biofaktor.pl

Portugal
Contact details to report suspected adverse reactions:
Laboratorios Syva S.A.
Parque Tecnológico de León
Calle Nicostrato Vela M15-M16
24009 LEÓN
ESPAÑA
Tel: + 351 219 747 934
E-mail: syva.portugal@syva.pt

Italia
Local representative:
IZO s.r.l. a socio unico
Via San Zeno 99/A
25124 Brescia - Italia
Tel: + 39 030 2420583
Contact details to report suspected adverse reactions:
IZO s.r.l. a socio unico
Tel: + 39 030 2420583
E-mail: pharmacovigilanza@izo.it

United Kingdom (Northern Ireland)
Local representative:
Zoetis UK Limited
1st Floor, Birchwood Building
Springfield Drive
Leatherhead
Surrey, KT22 7LP
UK
Tel: + 44 (0) 845 300 8034
Contact details to report suspected adverse reactions:
Zoetis UK Limited
Tel: + 44 (0) 845 300 8034

Slovenská republika
Contact details to report suspected adverse reactions:
VETSERVIS Ltd.
Tel: +421905748041
E-mail: supuka@vetservis.sk